天津中医药2017，Vol.34Issue(8)：522-524,3.DOI:10.11656/j.issn.1672-1519.2017.08.05
新肾康宁胶囊治疗早期高血压肾病的临床疗效观察
Clinical efficacy of observation new Shenkangning capsule in the treatment of early stage hypertensive nephropathy
摘要
Abstract
[Objective] To observe the clinical effect of the new new Shenkangning capsule in the treatment of early hypertensive nephropathy. [Methods] The essential hypertension patients with early renal injury in 60 cases, using random parallel control principle, divided into treatment group and control group with 30 cases in each group, two groups were treated with ACEI/ARB or calcium antagonist antihypertensive therapy, the treatment group at the same time with the Corelle kidney capsule, 4 pills, 3 times daily for 1 months the 1 course of treatment, after 3 courses of induction and the total scores of symptoms before and after treatment of urinary albumin and serum cystatin C (Cys-C) index changes, and statistical analysis. [Results] The treatment group in improving traditional Chinese medicine symptoms, urinary albumin (mAlb), serum Cys-C index changes were better than the control group (P<0.05). [Conclusion] The combination of new Shenkangning capsule can improve the clinical symptoms of early hypertensive nephropathy, reduce urinary albumin and serum cystatin index may be associated with improved renal ischemia, hypoxia, reduce glomerular sclerosis, delaying renal damage in patients with essential hypertension.关键词
新肾康宁胶囊/早期高血压肾病/尿微量白蛋白/血清胱抑素CKey words
new Shenkangning capsule/ early hypertensive nephropathy/ urinary albumin/ serrum cystatin C分类
医药卫生引用本文复制引用
周文均,孙岚云..新肾康宁胶囊治疗早期高血压肾病的临床疗效观察[J].天津中医药,2017,34(8):522-524,3.基金项目
国家中医药管理局"十一五"课题(2007 BAI10B01-006). （2007 BAI10B01-006）
